U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071519) titled 'A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis' on July 08.
Brief Summary: Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed.
Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being developed for ...